|1.||Green, Daniel M: 8 articles (01/2014 - 06/2003)|
|2.||Thompson, John F: 7 articles (03/2014 - 01/2006)|
|3.||Ritchey, Michael L: 7 articles (01/2014 - 06/2003)|
|4.||Breslow, Norman E: 7 articles (01/2014 - 09/2004)|
|5.||Shamberger, Robert C: 7 articles (01/2014 - 06/2003)|
|6.||Beckwith, J Bruce: 6 articles (01/2014 - 06/2003)|
|7.||Anderson, James R: 5 articles (11/2014 - 11/2009)|
|8.||Xiang, Yang: 5 articles (08/2014 - 06/2004)|
|9.||Kam, Peter C A: 5 articles (03/2014 - 05/2009)|
|10.||Thomas, Patrick R M: 5 articles (01/2014 - 09/2004)|
10/05/2003 - "As actinomycin D treatment in children with cancer is associated with veno-occlusive disease (VOD), and as the dose intensity of actinomycin D treatment has been defined as a significant risk factor for the development of this potentially life-threatening hepatic toxicity, pharmacokinetic studies of actinomycin D may be beneficial in optimizing treatment with this drug. "
01/01/1974 - "In addition, some evidence is cited suggesting that actinomycin D may be more effective against certain tumors when employed in lower, chronic dosages rather than its present use in "loading" dosages.The"
12/01/2013 - "In the present study, we reported that methylated actinomycin D (mAct D), a novel actinomycin D analog isolated from Streptomyces sp. KLBMP 2541 in our previous study, could not only exert stronger inhibitory effects on several human cancer cells than Act D in dose- and time-dependent manner at ng concentrations, especially on HepG2 cells, but also lower cytotoxicity in normal cells (HL-7702). "
08/15/2005 - "Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study."
01/01/1999 - "In this study, we showed that the p53 response to a chemotherapeutic drug, actinomycin D, was reversible in both normal and tumor cells, even when a substantial proportion of tumor cells were undergoing apoptosis. "
|2.||Wilms Tumor (Wilm's Tumor)
03/21/1966 - "Role of dactinomycin in the improved survival of children with Wilms' tumor."
09/19/1964 - "NEPHROBLASTOMA (WILMS' TUMOUR): IMPROVED PROGNOSIS WITH ACTINOMYCIN D."
07/25/1964 - "NEPHROBLASTOMA (WILMS' TUMOUR): IMPROVED PROGNOSIS WITH ACTINOMYCIN D."
09/01/2008 - "This phase 2 pediatric trial evaluated the efficacy and further defined the toxicity profile of recombinant TNF (rTNF) and dactinomycin in patients with recurrent or refractory Wilms tumor. "
12/01/2002 - "Clinical studies of actinomycin D with special reference to Wilms' tumor in children. "
|3.||Melanoma (Melanoma, Malignant)
05/01/1967 - "Induced remission of malignant melanoma with actinomycin D. "
05/01/2000 - "Autologous MABs from melanoma cells following actinomycin D treatment (0.5 microgram/ml) for 24 hours, were added to 72 hour DC culture. "
09/15/1998 - "Furthermore, addition of actinomycin D to TRAIL-resistant melanomas resulted in decreased intracellular concentrations of FLIP, which correlated with their acquisition of TRAIL sensitivity. "
05/01/1987 - "The presence of actinomycin D during gamma-irradiation of human melanoma cells leads to an increased radiosensitivity under aerobic and hypoxic conditions. "
05/01/1987 - "[The effect of actinomycin D on the survival and recoverability of irradiated human melanoma cells]."
08/01/2008 - "To evaluate response rate and disease-free interval in dogs with relapsed or resistant lymphoma treated with actinomycin D, determine hematologic toxicoses, and identify prognostic factors associated with response to treatment. "
09/01/1994 - "Actinomycin D for reinduction of remission in dogs with resistant lymphoma."
08/01/2008 - "Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006)."
10/01/1987 - "Actinomycin D was clastogenic and mutagenic in L5178Y/TK +/- -3.7.2C mouse lymphoma cells. "
01/01/2006 - "The results of this study warrant further investigation into the value of extended maintenance therapy and inclusion of actinomycin-D in combination chemotherapy protocols for canine lymphoma."
|5.||Ewing's Sarcoma (Sarcoma, Ewing)
04/01/1970 - "Treatment of metastatic Ewing's sarcoma with actinomycin D (NSC-3053)."
01/01/2004 - "In this study, we showed that etoposide and actinomycin D kill Ewing tumor cells (RD-ES cell line) mainly via a caspase-dependent mechanism. "
10/05/2003 - "Actinomycin D is an anti-cancer drug commonly used in the treatment of paediatric malignancies such as Wilms' tumour, Ewing's sarcoma and rhabdomyosarcoma. "
10/16/1991 - "Increasing dactinomycin dose intensity was associated with a poorer outcome in treatment of osteogenic sarcoma and Ewing's sarcoma, most likely resulting from regimens with a higher dactinomycin dose intensity having a lower doxorubicin dose intensity. "
01/01/1998 - "A higher rate of good responses was achieved with the use of ifosfamide and dactinomycin in addition to a conventional three-drug VAC regimen, suggesting that these drugs should be included from the beginning in neoadjuvant regimens for the treatment of Ewing's sarcoma. "
|4.||Etoposide (VP 16)
|8.||Vinblastine (Vinblastine Sulfate)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)